Domantis pockets $29M in new venture funds

Domantis has raised $29 million in new venture funds. New investors Novo Nordisk and MC Life Science Ventures--a subsidiary of Mitsubishi Corporation--led the round. "Domantis' twelve lead programs are based on novel dAb products for treating major diseases including COPD, rheumatoid arthritis, asthma and colorectal cancer," said Domantis CEO Robert Connelly. "This financing, together with the growing revenue stream from our nine partnerships, provides sufficient resources to fund the clinical development of these programs." Domantis is based in Waltham, MA and the UK.

- read this release for more information

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.